American Renal Associates Holdings, Inc. Securities Litigation (2019)

If you purchased a significant amount of shares of American Renal Associates Holdings, Inc (NYSE: ARA), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:American Renal Associates Holdings, Inc
Date Filed:March 28th, 2019
Sector:Health Care
Industry:Hospital/Nursing Management

According to the Complaint, American Renal purports to operate as a dialysis services provider in the United States.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) issues with American Renal's accounting process for revenue recognition, collections, and related matters would give rise to a U.S. Securities and Exchange Commission ("SEC") investigation into the same, and increased regulatory scrutiny by the SEC; (2) American Renal's financial statements for the fiscal years 2014, 2015, 2016 and 2017 contained in its Annual Reports for the years ended December 31, 2016 and 2017, and its condensed consolidated financial statements in quarterly reports from 2016 through 2018 were false and could not be relied upon; (3) American Renal had material weaknesses in its internal control over financial reporting; and (4) as a result, Defendants' public statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for American Renal Associates Holdings, Inc

 
First Identified Complaint

Ali Vandevar, et al. v. American Renal Associates Holdings, Inc., et al.

Date Filed:March 28th, 2019
Class Period Start:August 10th, 2016
Class Period End:March 27th, 2019
First Identified Complaint Filings
#Document TitleFiling Date